Hubert Fernandez, IAPRD 2018 – Highlights from the Scientific Program Executive Committee Chair
Chair of the IAPRD 2018 Scientific Program Executive Committee, Hubert Fernandez (Cleveland Clinic, Cleveland, OH, US), discusses identification of patients with Parkinson’s disease (PD) at risk of cognitive decline, the advantages of levodopa-carbidopa intestinal gel in advanced PD, recent exciting advances in PD therapy, as well as strengths and highlights of this year’s meeting.
1. How can we best identify patients with Parkinson’s disease (PD) at risk of cognitive decline? (0:14)
2. What are the advantages of levodopa-carbidopa intestinal gel in advanced PD? (3:00)
1. What do you consider the most exciting advances in PD therapy in recent years? (0:14)
2. What do consider are the greatest strengths of the IAPRD meeting? (3:57)
3. What do you expect to be the highlights of IAPRD 2018? (5:08)
Filmed at the XXII World Congress on Parkinson’s Diseases and Related Disorders (IAPRD), Lyon, France, August 2018.
Speaker disclosure (over the past 12 months).
Grants/Research Support: Dr. Fernandez has received research support from Abbvie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, but has no owner interest in any pharmaceutical company.
Honoraria: Dr. Fernandez has received honoraria from Prime Education Inc. International Parkinson and Movement Disorders Society, Carling Communications, Medscape, as a speaker in CME events. Dr. Fernandez has received honoraria from AbbVie, Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Medscape, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer Pharmaceuticals, as a consultant.
Royalty: Dr. Fernandez has received royalty payments from Demos Publishing for serving as a book author/editor.
Contractual Services: The Cleveland Clinic has a contract with Teva for Dr. Fernandez’ role as a Co-Principal Investigator in SD-809 Tardive Dyskinesia global studies. Dr. Fernandez also serves as a member of the publication committee for Acorda Pharmaceuticals but does not receive any personal compensation for these.
Other: Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site.
Share this Video
Related Videos In Parkinson's Disease
Veronica Clark, Parkinson’s Europe: Presidential Update, and the Parkinson’s Manifesto for Europe
The European Parkinson’s Disease Association (EPDA) recently changed its name to Parkinson’s Europe. They are the only European Parkinson’s umbrella organisation and have been working with the global Parkinson’s community for nearly 30 years. As a leading voice for Parkinson’s in Europe, they provide trusted information; advance and share good practices; raise awareness and improve […]
Suman Kushwaha, MDS 2022: COVID-19 vaccine induced parkinsonism and cognitive dysfunction
Two cases of COVID-19 vaccination associated neurological symptoms were presented, with patients displaying parkinsonism and cognitive dysfunction. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behaviour and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms and investigations leading to the case report conclusions. The abstract entitled […]
Suman Kushwaha, MDS 2022: Neurological symptoms and COVID-19 vaccination
Neurological complications, such as peripheral neuropathy, have been associated with COVID-19 vaccination. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behavior and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms that have been observed. The abstract entitled ‘Covid vaccine induced parkinsonism and cognitive dysfunction’ was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!